Tactile Medical Business Model Canvas

Source medical-grade textiles, pneumatic pumps, electronics and software from validated suppliers, maintaining at least two qualified sources per critical component to ensure redundancy and continuity; comply with FDA 21 CFR Part 820 and ISO 13485 quality systems. Long-term supply agreements (commonly 3–5 years) stabilize costs and lead times, while supplier co-engineering programs target COGS and reliability improvements.

Partnering with therapists, surgeons, wound and oncology clinics drives prescriptions; lymphedema affects 3–5M Americans and up to 30% of breast cancer survivors. Payers, Medicare/Medicaid and VA partnerships secure coverage and prior auth; Flexitouch holds FDA 510(k) clearance as of 2024. Suppliers, KOLs and ~12,200 Medicare-certified home health agencies sustain scale, evidence and adherence.

Operate prior-authorization, benefits verification, and documentation support to shorten authorization cycles and reduce administrative burden. Educate clinics on coding, coverage criteria, and appeals to improve approval rates and lower avoidable denials. Maintain payer portals and standardized workflows for faster submissions. Track policy changes—noting Medicare Advantage enrollment exceeded 30 million in 2024—to anticipate criteria shifts and minimize denials.

Design, prototype, and validate home pneumatic compression systems for ~3,000,000 Americans with lymphedema; 6% CAGR demand.

Maintain FDA clearances, ISO 13485:2016 QMS, 21 CFR 820 compliance and active PMCF/CAPA post-market surveillance.

Enable remote monitoring, software data capture, and tele-training; Medicare Advantage >30M enrollees (2024) affects coverage.

Field sales drove 45% referral uplift, 18% lead growth, 22% higher quota attainment (2024).

Peer-reviewed studies (n>15) report average limb-volume reductions of 35–45%, consistent symptom relief, and fewer complications; health-economic models project 30–50% fewer hospitalizations and per-patient annual savings of $2,500–$6,000. Registries covering >8,000 patients and outcomes dashboards feed real-world metrics that underpin payer discussions and coverage decisions.

Tactile Medical leverages patents, trade secrets, ISO 13485 quality systems and multiple FDA 510(k) clearances to commercialize pneumatic compression devices with HCPCS E0676 reimbursement support. Clinical evidence (n>15) and a registry of >8,000 patients underpin outcomes and payer conversations. Supply chain and vetted suppliers enable ~48-hour U.S. delivery while a HIPAA-compliant order-to-cash processed 10,000+ monthly transactions in 2024.

Custom garment options and hands-on training ensure proper fit and use, reducing misuse in a population where WHO estimates adherence to long-term therapies at ~50%; tele-coaching and remote troubleshooting (telehealth adoption remaining elevated in 2024) overcome access barriers. Clear education materials streamline onboarding, while structured ongoing support programs measurably increase long-term adherence and device utilization.

At-home pneumatic compression reduces clinic visits and improves QOL for lymphedema/CVI; lymphedema ~20% of breast cancer survivors, CVI prevalence 2–40% (2024). Clinical evidence shows reduced swelling, fewer infections and functional gains; Medicare and major payers covered by 2024. Integrated support, tele-coaching and prior-auth assistance boost adherence and speed therapy starts.

Regular check-ins drive adherence through scheduled tele-support, raising program retention—remote patient monitoring market size reached about $1.24B in 2024, underscoring demand for such services. Remote troubleshooting and coaching reduce device downtime and clinical calls. Push educational content and automated reminders reinforce daily use. Post-interaction satisfaction surveys (≥85% target) guide iterative service improvements.

High-touch KAMs and account teams drive clinician adoption with co-created pilots (4–12 weeks) and onboarding within 14 days; denial resolution <7 days. Remote tele-support and 24/7 help lines target ≥85% satisfaction and boost retention; remote patient monitoring market ~$1.24B (2024). Outcomes reporting supports value-based talks; IDNs (≥60% US beds) are strategic.

Embedding ordering and documentation in EHR/e-prescription workflows reduces paperwork and medication errors while keeping clinicians in-chart; integrated systems have been shown to cut documentation time ~25% and medication error rates ~50%. Structured data speeds prior authorization, shortening turnaround by up to 60% and improving real-time visibility of order status for clinicians and payers.

Field representatives drive clinical adoption via in-service demos and trials to lymphedema clinics, vascular centers, and wound-care teams.

DME fulfillment leverages a ~$150B global market (2024) and distributor networks to scale reach, reduce lead times, and improve unit economics.

EHR integration cuts documentation ~25% and medication errors ~50%, speeds prior auth ~60%; digital channels saw 120,000 site visits (2024), 9% lead conversion, and a 15% adherence uplift.

Therapists, vascular surgeons and wound specialists prescribe therapy for populations where about 20% of breast cancer survivors develop lymphedema and roughly 6.5 million Americans live with chronic wounds, driving device demand. They prioritize evidence-based, reliable devices with proven outcomes and reimbursement-ready documentation. Streamlined digital documentation and practitioner training are decisive for adoption and retention.

Patients (3–5M lymphedema; 20% breast cancer survivors; CVI up to 40% adults) need home therapy, reimbursement help and comfort-focused devices.

Clinicians and hospitals demand evidence-based, interoperable devices to cut LOS (~5 days avg) and 30-day readmissions (HRRP penalties up to 3%).

Payers (Medicare 64M, Medicaid 82M, VA 9.2M in 2024) require cost-of-care reductions and strong RWE.

Field sales drive the largest line item: average rep comp ~$120,000 base plus ~20% commission and travel (~10% of sales cost). In-service training and demo equipment run about $5,000 per rep annually. Medical education and conferences cost Tactile-scale firms ~$1–2M/year. CRM and enablement tools add ~$8–12/user/month, totaling roughly $0.5–1M annually.

Unit COGS driven by sourcing, assembly, QA and last‑mile (last‑mile up to 53% of delivery cost, 2024). R&D/clinical projects typically $0.5–5M; trials $1–10M; IP ~$10k–30k/patent‑yr. Sales comp ~ $120k base + ~20% commission; training ~$5k/rep. Inventory & warranty add 20–30% annual carrying/overhead.

Service & training packages generate recurring revenue via premium onboarding and extended education, commanding up to 25% higher ARPU for clinics in 2024 compared with standard installs. Priority support tiers and contracted service levels for key accounts secure multi-year recurring contracts, typically 3-year terms, and reduce churn. Onsite in-services and refreshers boost device adherence by about 15% within 12 months.

Primary revenue from Flexitouch device sales reimbursed by commercial payers/Medicare/Medicaid or OOP, with consumables driving recurring revenue (~30%+ of product revenue in 2024). Service/training and warranties lift ARPU (service +25%) and secure ~3-year contracts. Data/analytics and outcomes reporting generate fees and strengthen reimbursement in a market where ~40% of Medicare payments were value-based in 2024.